AstraZeneca is to acquire French infection research company, Novexel, for US$350 M in cash. After completion of the acquisition, in a related deal, Forest Laboratories will pay back US$210 M to AstraZeneca for rights in the USA to two combination late-stage antibiotics that treat multidrug resistant bacteria.